安宮牛黃丸聯合依達拉奉右莰醇治療腦梗死急性期的效果及對NSE、血清S100β蛋白的影響

【摘要】 目的：探究安宮牛黃丸聯合依達拉奉右莰醇治療腦梗死急性期的效果。方法：選取2020年12月—2022年12月贛南醫學院第一附屬醫院收治的100例腦梗死急性期患者，按隨機數字表法分為對照組和試驗組，各50例。對照組采取傳統保守治療方案，試驗組在對照組基礎上采用安宮牛黃丸聯合依達拉奉右莰醇治療。比較兩組治療14 d的效果，治療前、治療1、7、14 d的美國國立衛生研究院卒中量表（NIHSS）評分、血清神經元特異性烯醇化酶（NSE）、血清S100鈣結合蛋白β（S100β）蛋白。結果：治療14 d后，試驗組總有效率較對照組高（Plt;0.05）。兩組治療1、7、14 d的NIHSS評分、血清NSE、S100β蛋白均低于治療前，治療7、14 d的上述評分及指標均低于治療1 d，治療14 d的上述評分及指標低于治療7 d，試驗組治療1、7、14 d的上述評分及指標均低于對照組，差異均有統計學意義（Plt;0.05）。結論：安宮牛黃丸聯合依達拉奉右莰醇治療腦梗死急性期的效果顯著，可有效改善患者血清NSE、S100β蛋白，減輕神經功能缺損程度。

【關鍵詞】 腦梗死急性期 安宮牛黃丸 依達拉奉右莰醇 神經元特異性烯醇化酶 S100鈣結合蛋白β

Effect of Angong Niuhuang Pills Combined with Edaravone and Dexborneol in the Treatment of Acute Cerebral Infarction and Its Influence on NSE and Serum S100β Protein/CAO Jie， LIU Nanhai， LIAO Wei. //Medical Innovation of China， 2023， 20（31）： 0-072

[Abstract] Objective： To explore the effect of Angong Niuhuang Pills combined with Edaravone and Dexborneol in the treatment of acute cerebral infarction. Method： A total of 100 patients with acute cerebral infarction admitted to First Affiliated Hospital of Gannan Medical College from December 2020 to December 2022 were selected and divided into the control group and the experimental group according to the random number table method， with 50 cases in each group. The control group was treated with traditional conservative treatment， while the experimental group was treated with Angong Niuhuang Pills combined with Edaravone and Dexborneol on the basis of the control group. The effect of 14 days of treatment， the national institutes of health stroke scale （NIHSS） score， serum neuron specific enolase （NSE） and serum S100 calcium-binding protein β （S100β） protein before treatment and 1， 7 and 14 d of treatment were compared between the two groups. Result： After 14 days of treatment， the total effective rate of the experimental group was higher than that of the control group （Plt;0.05）. The NIHSS score， serum NSE， S100β protein of the two groups on the 1， 7 and 14 d of treatment in the two groups were lower than those before treatment， the above scores and indexes on 7 and 14 d of treatment were lower than those on 1 d of treatment， the above score and indexes on 14 d of treatment were lower than those on 7 d of treatment， the above scores and indexes in the experimental group on the 1， 7 and 14 d of treatment were lower than those in the control group， the differences were statistically significant （Plt;0.05）. Conclusion： Angong Niuhuang Pills combined with Edaravone and Dexborneol in the treatment of acute cerebral infarction， which can effectively improve serum NSE and S100β protein and reduce the degree of neurological deficit.

[Key words] Acute cerebral infarction Angong Niuhuang Pills Edaravone and Dexborneol Neuron-specific enolase S100 calcium-binding protein β

First-author's address： First Affiliated Hospital of Gannan Medical College， Ganzhou 341000， China

doi：10.3969/j.issn.1674-4985.2023.31.016

腦梗死急性期發病較突然，病情進展較快，如不及時治療，將會導致患者出現癱瘓、意識障礙等[1]。溶栓、取栓治療早期腦梗死急性期患者效果較好，但受技術設備以及時間窗的影響，部分患者不符合溶栓、取栓適應證，只能接受控制血壓血糖、吸氧、抗血小板、抗凝、清除氧自由基等保守治療。但保守治療效果不理想，不利于腦梗死急性期患者神經功能的恢復，需尋求更有效的治療方案。……